Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Eye Care

Expert Opinion / Commentary · December 05, 2022

2022 Top Story in Eye Care: Bevacizumab in the Treatment of Retinopathy of Prematurity

Written by
Aparna Ramasubramanian MD


Additional Info

  1. Blencowe H, Lawn JE, Vazquez T, et al. Preterm-Associated Visual Impairment and Estimates of Retinopathy of Prematurity at Regional and Global Levels for 2010. Pediatr Res. 2013;74(Suppl 1):35–49.
  2. Quinn GE, Ying GS, Bell EF, et al. Incidence and Early Course of Retinopathy of Prematurity: Secondary Analysis of the Postnatal Growth and Retinopathy of Prematurity (G-ROP) Study. JAMA Ophthalmol. 2018;136(12):1383–1389.
  3. Hellström A, Smith LEH, Dammann O. Retinopathy of Prematurity. Lancet. 2013;382(9902):1445–1457.
  4. Mintz-Hittner HA, Kennedy KA, Chuang AZ. Efficacy of Intravitreal Bevacizumab for Stage 3+ Retinopathy of Prematurity. N Engl J Med. 2011;364(7):603–615.
  5. Connor AJ, Papastavrou VT, Hillier RJ, et al. Ultra-Low Dose of Intravitreal Bevacizumab in the Treatment of Retinopathy of Prematurity. J Pediatric Ophthalmol Strabismus. 2015 Apr 30. doi: 10.3928/01913913-20150421-11. Online ahead of print.
  6. Shafiq A, Hillier R, Hearn R. Contralateral Effect of Systemic Absorption of Low Dose Bevacizumab (Avastin) After Unilateral Intravitreal Injection in Severe Retinopathy of Prematurity (ROP). BMJ Case Rep. 2020 Mar 12. doi: 10.1136/bcr-2019-232359. Online ahead of print.
  7. Freedman SF, Hercinovic A, Wallace DK, et al. Low- and Very Low-Dose Bevacizumab for Retinopathy of Prematurity: Reactivations, Additional Treatments, and 12-Month Outcomes. Ophthalmology. 2022;129(10):1120–1128.
  8. Hartnett ME, Wallace DK, Dean TW, et al. Plasma Levels of Bevacizumab and Vascular Endothelial Growth Factor After Low-Dose Bevacizumab Treatment for Retinopathy of Prematurity in Infants. JAMA Ophthalmol. 2022;140(4):337–344.

Disclosure statements are available on the authors' profiles:

Further Reading